Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
Adil I Daud, Jana Dawson, Ronald C DeConti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2008
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
Adil I Daud, Noweeda Mirza, Brianna Lenox, et al.
BMC Cancer
|
April 3, 2026
Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma
Olivia Sleeper, Justin Fortino, Nam Woo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
Anthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
June 18, 2026
The paradox of escalating immunotherapy for uveal melanoma liver metastases
Paul Wong, Tommaso Pollini, Sophia Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2008
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Adil I Daud, Ronald C DeConti, Stephanie Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2011
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies
Mayer N Fishman, John A Thompson, Gregory K Pennock, et al.
Cancer Immunology Research
|
December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
Samantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 23, 2013
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch, Homayoun Moslehi, Luzviminda Feeney, et al.
Nature Communications
|
January 21, 2026
PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells
Sixuan Pan, Inés Fernández-Maestre, Kai-Chun Chang, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
Adil I Daud, Jana Dawson, Ronald C DeConti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2008
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
Adil I Daud, Noweeda Mirza, Brianna Lenox, et al.
BMC Cancer
|
April 3, 2026
Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma
Olivia Sleeper, Justin Fortino, Nam Woo Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
Anthony W Tolcher, Alain Mita, Lionel D Lewis, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
June 18, 2026
The paradox of escalating immunotherapy for uveal melanoma liver metastases
Paul Wong, Tommaso Pollini, Sophia Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2008
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Adil I Daud, Ronald C DeConti, Stephanie Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2011
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies
Mayer N Fishman, John A Thompson, Gregory K Pennock, et al.
Cancer Immunology Research
|
December 20, 2019
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
Samantha K Greaney, Alain P Algazi, Katy K Tsai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 23, 2013
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch, Homayoun Moslehi, Luzviminda Feeney, et al.
Nature Communications
|
January 21, 2026
PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells
Sixuan Pan, Inés Fernández-Maestre, Kai-Chun Chang, et al.
Page
of 9